Sanofi Pasteur to Add 2D Barcode to Additional Vaccines

MENACTRA (Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine) by Sanofi Pasteur
MENACTRA (Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine) by Sanofi Pasteur

Sanofi Pasteur announced it will transition six products of its pediatric vaccine portfolio to two-dimensional (2D) barcoding technology by the beginning of 2013.

Below is the schedule for the roll out of the vaccines that will feature the 2D barcode:

  • Q3, 2012: Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) vaccine; Fluzone (Influenza Virus Vaccine) unit-dose vials
  • Q4, 2012: Daptacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) vaccine; Tenivac (Tetanus and Diphtheria Toxoids Adsorbed) vials; IPOL (Poliovirus Vaccine Inactivated) in multi-dose vial presentation
  • Q1, 2013: Pentacel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate]) vaccine

The Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) and Diphtheria and Tetanus Toxoids Adsorbed (for Pediatric use) vaccines are now shipping with the 2D barcode.

In December 2011, Sanofi Pasteur became the first vaccine company to launch the new technology, which is designed to reduce medical errors and help health care providers document vaccine information in patient records with greater accuracy by offering more product information. Sanofi Pasteur participated in a group led by the American Academy of Pediatrics (AAP) and the U.S. Centers for Disease Control and Prevention (CDC) that included key partners such as the U.S. Food and Drug Administration (FDA); GS1, an internationally-recognized organization dedicated to the development of global standards; and multiple manufacturers, to develop a single standard for the 2D barcode on vaccines.

Two-dimensional barcodes contain more data, including lot numbers, expiration dates, global trade identification numbers, and national drug codes, than was possible in standard linear barcodes. The barcodes are printed on the "unit-of-use," or the vials and syringes that contain the vaccines.

Sanofi Pasteur does not currently plan to remove the linear barcode. The linear barcode is required by the FDA. Sanofi will also continue to have the human readable information so that offices without scanning technology can still easily record information in patient records.

To aid adoption of the technology by physicians, AAP has developed a clinical guidance for physicians to help practices use 2D barcoding with their electronic medical record (EMR) or state immunization information system (registry) www.aap.org/immunization. The CDC is also assessing the technology for vaccines in a pilot program, which begins in August. Details of the pilot can be found at www.2dbarcodepilot.com.

Reading the new 2D barcode requires an EMR system, in addition to a compatible 2D scanning device. Information and pricing on the required scanners is available at www.vaxserve.com.

For more information call (800) VACCINE or visit www.sanofipasteur.com.